Literature DB >> 10818187

Unusual electrocardiogram findings in a preterm infant after fetal tachycardia with hydrops fetalis treated with flecainide.

A Trotter1, M Kaestner, F Pohlandt, D Lang.   

Abstract

Fetal tachycardia and signs of hydrops fetalis were diagnosed at 29 weeks of gestation. The heart rate normalized by combined treatment with digoxin and flecainide and was followed by improvement of the hydrops. Premature labor led to delivery at 33 weeks of gestation. The newborn infant showed mild respiratory distress and was in a hemodynamically stable condition. Marked QT segment anomalies on the electrocardiogram during the first postnatal days resolved completely within 3 weeks. They were unlikely to be attributable to myocarditis or myocardial infarction. We speculate that these anomalies were caused by the maternal flecainide therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10818187     DOI: 10.1007/s002460010053

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  5 in total

Review 1.  Fetal cardiac arrhythmia detection and in utero therapy.

Authors:  Janette F Strasburger; Ronald T Wakai
Journal:  Nat Rev Cardiol       Date:  2010-05       Impact factor: 32.419

Review 2.  Drug treatment of fetal tachycardias.

Authors:  Martijn A Oudijk; Jopje M Ruskamp; Barbara E Ambachtsheer; Tessa F F Ververs; Philip Stoutenbeek; Gerard H A Visser; Erik J Meijboom
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 3.  Overview of fetal arrhythmias.

Authors:  Shardha Srinivasan; Janette Strasburger
Journal:  Curr Opin Pediatr       Date:  2008-10       Impact factor: 2.856

Review 4.  Perinatal arrhythmias: diagnosis and management.

Authors:  Janette F Strasburger; Bageshree Cheulkar; Heather J Wichman
Journal:  Clin Perinatol       Date:  2007-12       Impact factor: 3.430

Review 5.  Fetal Arrhythmia Diagnosis and Pharmacologic Management.

Authors:  Janette F Strasburger; Gretchen Eckstein; Mary Butler; Patrick Noffke; Annette Wacker-Gussmann
Journal:  J Clin Pharmacol       Date:  2022-09       Impact factor: 2.860

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.